RobertSokolicMDFACP(He/Him)
Oncology • Silver Spring, MDHematologic Oncology
Medical Officer, CBER, FDA
Dr. Sokolic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10903 New Hampshire Ave
Silver Spring, MD 20903
Summary
- Hematologist-oncologist with clinical, research, industry and regulatory experience in cell and gene therapy for hematologic malignancies, solid tumors, sickle cell disease, primary immunodeficiencies, storage disorders and rare diseases
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 2002
University of Pennsylvania Health SystemResidency, Internal Medicine, 1996 - 1998
The Warren Alpert Medical School of Brown UniversityClass of 1996
Certifications & Licensure
RI State Medical License 2017 - 2026
MA State Medical License 2024 - 2025
NY State Medical License 1998 - 2025
CT State Medical License 2023 - 2024
DC State Medical License 2017 - 2018
MD State Medical License 2015 - 2017
PA State Medical License 1997 - 1998- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Molecular and Clinical Studies of Primary Immunodeficiency Diseases Start of enrollment: 2000 Oct 25
- Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency Start of enrollment: 2001 Jun 20
- Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents Start of enrollment: 2010 Aug 05
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsWiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival.Tanja C Vallée, Jannik S Glasmacher, Hannes Buchner, Peter D Arkwright, Uta Behrends
Blood. 2024-06-13 - 26 citationsLong-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiencyBryanna Reinhardt, Omar Habib, Kit L. Shaw, Elizabeth Garabedian, Denise A. Carbonaro-Sarracino
Blood. 2021-10-14 - 94 citationsAutologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency.Donald B. Kohn, Claire Booth, Kit L. Shaw, Jinhua Xu-Bayford, Elizabeth Garabedian
The New England Journal of Medicine. 2021-05-11
Professional Memberships
- Fellow
- Member
- Member
- Member
- American Society of Blood and Marrow TransplantationMember
- American Society of Cell and Gene TherapyMember
- Clinical Immunology SocietyMember
- European Society for Immune DeficiencyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
